{"id":"W4399300859","doi":"10.1016/s0140-6736(24)00885-7","title":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Foghorn Therapeutics; Servier; National Cancer Institute; Chugai Pharmaceutical; Genentech; European Network for Rare Adult Solid Cancers; Ipsen; PharmaMar; European Society for Medical Oncology; AstraZeneca; Institut National Du Cancer; Pfizer; Symphogen; Incyte; Amgen; Deciphera Pharmaceuticals; Connective Tissue Oncology Society; Karyopharm Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; Iterion Therapeutics; Sanofi; Les Laboratories Pierre Fabre","keywords":"Medicine; Placebo; Clinical endpoint; Population; Surgery; Clinical trial; Internal medicine; Adverse effect; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001619064,0.002093708,0.00464636,0.0004524748,0.0005153082,0.001258497,0.001038398,0.002813939,0.007524115],"category_scores_gemma":[0.001872477,0.0007085226,0.003287297,0.0004438178,0.001159697,0.00130863,0.0004389987,0.003198709,0.001353652],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000805758,"about_ca_system_score_gemma":0.0009509402,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001183394,"about_ca_topic_score_gemma":0.002716137,"domain_scores_codex":[0.9994075,0.0002676191,0.00004415043,0.0001189618,0.00004111797,0.0001206001],"domain_scores_gemma":[0.9993654,0.0002133154,0.000161825,0.00004295552,0.00004994051,0.0001666664],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9858473,0.001132597,0.0001352734,0.001520083,0.0009981308,0.00003368338,0.0000333584,0.0001679718,0.001481935,0.000100156,0.0007720246,0.007777459],"study_design_scores_gemma":[0.9805499,0.01780608,0.0004664743,0.0000611928,0.0003733512,0.00002291195,0.00001617757,0.0001432581,0.0001194381,0.000103908,0.0003257132,0.00001160772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9481208,0.03334231,0.001631532,0.001942548,0.003182512,0.005687888,0.002170447,0.0003661833,0.003555727],"genre_scores_gemma":[0.9739833,0.008671766,0.001833537,0.002082435,0.0008534082,0.005460571,0.001184442,0.00004227045,0.005888158],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007524115,"threshold_uncertainty_score":0.02517062,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05800919363486282,"score_gpt":0.3477364504843583,"score_spread":0.2897272568494954,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}